CN114641561A - 含有包含扩增和富集的超活化细胞因子杀伤t细胞群体的细胞产物的组合物及其制备方法 - Google Patents

含有包含扩增和富集的超活化细胞因子杀伤t细胞群体的细胞产物的组合物及其制备方法 Download PDF

Info

Publication number
CN114641561A
CN114641561A CN201980088899.8A CN201980088899A CN114641561A CN 114641561 A CN114641561 A CN 114641561A CN 201980088899 A CN201980088899 A CN 201980088899A CN 114641561 A CN114641561 A CN 114641561A
Authority
CN
China
Prior art keywords
cells
population
cell
scktc
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980088899.8A
Other languages
English (en)
Chinese (zh)
Inventor
徐建青
X·Y·张
J·王
L·Y·朱
B·W·鲁比特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sino American Biotechnology Holding Co
Original Assignee
Sino American Biotechnology Holding Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sino American Biotechnology Holding Co filed Critical Sino American Biotechnology Holding Co
Publication of CN114641561A publication Critical patent/CN114641561A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/36—Lipids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/05—Adjuvants
    • C12N2501/052—Lipopolysaccharides [LPS]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2312—Interleukin-12 (IL-12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1121—Dendritic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CN201980088899.8A 2018-11-13 2019-11-13 含有包含扩增和富集的超活化细胞因子杀伤t细胞群体的细胞产物的组合物及其制备方法 Pending CN114641561A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862760077P 2018-11-13 2018-11-13
US62/760077 2018-11-13
PCT/US2019/061191 WO2020102360A1 (en) 2018-11-13 2019-11-13 Compositions containing an expanded and enriched population of superactivated cytokine killer t cells and methods for making same

Publications (1)

Publication Number Publication Date
CN114641561A true CN114641561A (zh) 2022-06-17

Family

ID=70551406

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980088899.8A Pending CN114641561A (zh) 2018-11-13 2019-11-13 含有包含扩增和富集的超活化细胞因子杀伤t细胞群体的细胞产物的组合物及其制备方法

Country Status (7)

Country Link
US (1) US20210161955A2 (https=)
EP (1) EP3880794A4 (https=)
JP (1) JP2022520302A (https=)
CN (1) CN114641561A (https=)
AU (1) AU2019379140A1 (https=)
BR (1) BR112021009222A2 (https=)
WO (1) WO2020102360A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024222701A1 (zh) * 2023-04-25 2024-10-31 苏州沙砾生物科技有限公司 一种t细胞受体及其用途

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220401477A1 (en) * 2021-05-18 2022-12-22 Verdure Biotech, Inc. Method for controlling viral infections through adoptive transfer of a cell product comprising an expanded and enriched population of superactivated cytokine killer cells

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106011060A (zh) * 2016-06-29 2016-10-12 北京中台恒基生物技术有限公司 一种体外激活和扩增nkt样细胞的方法
CN106434556A (zh) * 2016-11-22 2017-02-22 上海市公共卫生临床中心 一种体外诱导扩增i型nkt细胞的方法
CN106434552A (zh) * 2015-08-13 2017-02-22 清华大学 新型nkt样细胞亚群及其治疗肿瘤的用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1288291A4 (en) * 2000-06-06 2004-05-12 Kirin Brewery METHOD FOR REPLACING NATURAL KILLER T CELLS
JP2011528326A (ja) * 2008-07-18 2011-11-17 セントクローネ インターナショナル エービー インビトロ拡大されたｔリンパ球及びガン治療に適切な血管形成インヒビターを含む組成物
WO2015112793A2 (en) * 2014-01-27 2015-07-30 St. Jude Children's Research Hospital, Inc. Methods of expanding ex vivo natural killer t (nkt) cells and therapeutic uses thereof
KR20190129046A (ko) * 2017-02-15 2019-11-19 더 리전트 오브 더 유니버시티 오브 캘리포니아 Nk 세포를 활성화시키기 위한 조성물 및 방법
EP4417210A1 (en) * 2017-03-15 2024-08-21 Orca Biosystems, Inc. Compositions and methods for hematopoietic stem cell transplants

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106434552A (zh) * 2015-08-13 2017-02-22 清华大学 新型nkt样细胞亚群及其治疗肿瘤的用途
CN106011060A (zh) * 2016-06-29 2016-10-12 北京中台恒基生物技术有限公司 一种体外激活和扩增nkt样细胞的方法
CN106434556A (zh) * 2016-11-22 2017-02-22 上海市公共卫生临床中心 一种体外诱导扩增i型nkt细胞的方法
WO2018095204A1 (zh) * 2016-11-22 2018-05-31 上海市公共卫生临床中心 一种体外诱导扩增i型nkt细胞的方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
黄勇, 姜尔烈, 周征, 何, 王玫, 刘庆国, 翟文静, 韩明哲: "经α-半乳糖酰基鞘氨醇体外扩增Vα24自然杀伤T细胞的生物学特性", 中国医学科学院学报, no. 03, 30 June 2005 (2005-06-30), pages 315 - 320 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024222701A1 (zh) * 2023-04-25 2024-10-31 苏州沙砾生物科技有限公司 一种t细胞受体及其用途

Also Published As

Publication number Publication date
EP3880794A4 (en) 2022-08-24
EP3880794A1 (en) 2021-09-22
AU2019379140A1 (en) 2021-06-24
US20210161955A2 (en) 2021-06-03
US20200147139A1 (en) 2020-05-14
WO2020102360A1 (en) 2020-05-22
JP2022520302A (ja) 2022-03-30
BR112021009222A2 (pt) 2021-08-10

Similar Documents

Publication Publication Date Title
TWI855499B (zh) 嵌合受體和使用彼之方法
KR102812405B1 (ko) γδ T 세포의 증식, 조성물 및 이의 사용 방법
Trzonkowski et al. Ex vivo expansion of CD4+ CD25+ T regulatory cells for immunosuppressive therapy
US9309321B2 (en) Monoclonal antibody specifically recognizing an epitope for switching to Th17 cell
Schreibelt et al. Commonly used prophylactic vaccines as an alternative for synthetically produced TLR ligands to mature monocyte-derived dendritic cells
TWI865517B (zh) 抗利妥昔單抗嵌合抗原受體及其用途
Brady et al. Tumor-associated macrophages: Prognostic and therapeutic targets for cancer in humans and dogs
TW202003837A (zh) 表現趨化因子受體及細胞接著分子之cd3陰性細胞之集團、及其用途及其製造方法
CN114641561A (zh) 含有包含扩增和富集的超活化细胞因子杀伤t细胞群体的细胞产物的组合物及其制备方法
Nishikawa et al. Induction of regulatory T cell–resistant helper CD4+ T cells by bacterial vector
US20250367235A1 (en) Systems and methods for modulating a cell phenotype
US20250041344A1 (en) Gene editing methods for modulating expression of id-3, an inhibitor of dna-binding transcription factors, thereby affecting t-cell function
TW201803984A (zh) 有效率的ｎｋｔ細胞活化技術
JP5717116B2 (ja) 抗原特異的ヒトＴｈ１７細胞を調整する方法
US20260102494A1 (en) Molecular engineering to enhance car-t mediated tumor immunotherapy
TWI917318B (zh) 靶向ｄｌｌ３的嵌合抗原受體和結合劑
Larson Identifying and Overcoming Resistance to CAR T Cell Therapy in Solid and Liquid Tumors
US20250101113A1 (en) Anti-cd94 antibody and chimeric antigen receptor and methods of use thereof
US20230407252A1 (en) Methods for donor cell analysis
Mengyun Antigen-specificity and lineage relationship of circulating T follicular helper cells in humans
Azizov Acetate modulates T cell dependent humoral immune response in secondary lymphoid organs
Stavrou Investigating the immunosuppressive microenvironment created by acute myeloid leukaemia using invariant natural killer T cells as a novel therapeutic approach
Rhee Regulation of T follicular helper cells in the germinal center reaction of chronic graft-versus-host disease
Palmer Comparing how the microenvironments of the skin and lung shape T cell responses to vaccination
McMonigle Delineation Of B Cell Follicle Associated Cd4+ T Cell Subsets

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220617